Amarin Corporation plc
NASDAQ:AMRNBiotechnology
+$0.29 today
- Market cap
- $232.89M
- Beta
- 0.82
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$1.62
Volume 0.09M
Average 0.07M
AMRN Total Debt
Short-term and long-term borrowings combined.
Amarin Corporation plcNASDAQ: AMRN
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 29.7% from a year ago
Total debt stood at $5.59M at the end of Q1 FY2026, down 29.7% from a year earlier and down 54.1% from the prior quarter. Over 3 fiscal years it compounded at +6.7% a year.
Context
- Total debt amounted to 0.9% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -29.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 12.16M USD
- Year-over-year change
- +57.5%
- 4-year CAGR
- +9.1%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.16M | +57.5% |
| FY2024 | 2024-12-31 | 7.72M | -11.6% |
| FY2023 | 2023-12-31 | 8.74M | -12.8% |
| FY2022 | 2022-12-31 | 10.02M | +16.8% |
| FY2021 | 2021-12-31 | 8.58M | — |
Total Debt vs competitors
How AMRN compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -29.7% is the 9th highest of 11, against a peer median of -9.8%.
- Total debt amounts to 0.9% of total assets for AMRN, versus a peer median of 4.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $108.6M USD | +18.3% | +16.5% | 37.6% | |
| Mar 2026 | $48.85M USD | -14.4% | -9.0% | 13.9% | |
| Mar 2026 | $42.89M USD | -5.1% | -36.1% | 23.4% | |
| Mar 2026 | $35.85M USD | +2158.8% | +216.7% | 10.7% | |
| Mar 2026 | $16.3M USD | +32.0% | +73.5% | 6.1% | |
ENGNenGene Holdings Inc. | Apr 2026 | $8.25M USD | -67.5% | -0.3% | 2.7% |
| Mar 2026 | $5.69M USD | -78.5% | -62.3% | 2.1% | |
| Mar 2026 | $5.59M USD | -29.7% | +6.7% | 0.9% | |
| Mar 2026 | CHF 4.3M CHF | -16.8% | +17.5% | 3.1% | |
| Mar 2026 | $3.78M USD | -22.3% | -9.1% | 1.8% | |
| Mar 2026 | $136K USD | +126.7% | -28.9% | 0.1% | |
| Peer median (excluding AMRN) | — | -9.8% | -4.7% | 4.6% | |
Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 219.45M | 217.67M | 199.25M | 121.04M | 134.86M |
| Short-term Investments | 234.67M | 91.7M | 121.41M | 173.18M | 167.93M |
| Net Receivables | 163.65M | 130.99M | 133.56M | 122.28M | 126.83M |
| Inventory | 234.68M | 228.73M | 258.62M | 166.05M | 195.91M |
| Other Current Assets | 3.92M | 20.02M | 525K | 12.85M | 24.35M |
| Total Current Assets | 878.73M | 689.1M | 724.98M | 595.4M | 649.88M |
| Property, Plant & Equipment (Net) | 9.09M | 9.95M | 8.42M | 7.61M | 6.47M |
| Goodwill | 0 | 0 | 0 | 0 | 13.36M |
| Intangible Assets | 23.55M | 21.78M | 19.3M | 16.39M | 0 |
| Long-term Investments | 35M | 1.28M | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 121.71M | 164.08M | 78.98M | 65.95M | 1.06M |
| Total Non-current Assets | 189.34M | 197.08M | 106.7M | 89.95M | 20.89M |
| Total Assets | 1.07B | 886.18M | 831.68M | 685.35M | 670.77M |
| Account Payables | 114.92M | 64.6M | 52.76M | 40.37M | 45.35M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 2.65M | 2.2M | 2.34M | 0 | 0 |
| Other Current Liabilities | 45.6M | 35.64M | 185.23M | 17.55M | 149.1M |
| Total Current Liabilities | 370.68M | 259.48M | 259.28M | 179.95M | 194.46M |
| Long-term Debt | 0 | 0 | 0 | 0 | 6.08M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 14.06M | 13.15M | 2.51M | 0 | 0 |
| Other Non-current Liabilities | 7.65M | 8.21M | 9.06M | 11.5M | 4.87M |
| Total Non-current Liabilities | 30.28M | 31.37M | 20.31M | 19.22M | 17.03M |
| Total Liabilities | 400.97M | 290.85M | 279.59M | 199.17M | 211.49M |
| Common Stock | 294.03M | 299M | 302.76M | 305.3M | 310.18M |
| Retained Earnings | (1.42B) | (1.53B) | (1.59B) | (1.67B) | (1.71B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 667.1M | 595.33M | 552.1M | 486.18M | 459.28M |
| Total Debt | 8.58M | 10.02M | 8.74M | 7.72M | 12.16M |
| Net Debt | (210.88M) | (207.65M) | (190.52M) | (113.32M) | (122.7M) |
Amarin Corporation plc
NASDAQ:AMRN
Intrinsic Alpha fair value
Locked
Current Price
$11.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.